Top 10 European Pharmaceutical Tech Companies

BioNTech, founded in Mainz by Uğur Şahin and Özlem Türeci, spent a decade on mRNA cancer immunotherapy before partnering with Pfizer to turn the same platform into the Comirnaty COVID-19 vaccine in 2020. Oncology remains its stated main purpose, and its pipeline centres on individualised neoantigen vaccines and mRNA-encoded antibodies.

UCB is a Belgian biopharma focused on neurology and immunology. Its growth now comes largely from Bimzelx (bimekizumab), the first antibody to block both IL-17A and IL-17F, alongside an epilepsy franchise that includes Fintepla for Dravet syndrome and Lennox-Gastaut. It also runs an anti-tau Alzheimer's programme, bepranemab, partnered with Roche.

Evotec runs the world's largest open-innovation pharma network, with its Hamburg-based platform generating nearly €800M revenue and analyzing over 500B data points. Its AI engine cuts average hit-to-lead timelines by 65%; partners include Bayer, Novo Nordisk, and Bristol Myers Squibb.

Exscientia, an Oxford-based drug discovery company, put the first AI-designed drug molecule into human trials in 2020, using its Centaur Chemist platform to compress the design-make-test cycle of early-stage medicinal chemistry. It was acquired by Recursion Pharmaceuticals in November 2024 and no longer operates as a standalone company.

Owkin pioneered federated learning for clinical data, allowing AI models to train on hospital data without it leaving the institution; valued at $1B+, its MSI biomarker predictor is approved for colorectal cancer diagnosis in France, deployed in 25+ European oncology centres.

Recursion is a Salt Lake City drug-discovery company that runs automated cell-imaging experiments at industrial scale and trains models on the resulting petabyte-scale image dataset to find drug-disease relationships. It signed a Roche and Genentech collaboration in 2021 covering up to 40 programmes, and acquired the UK AI drug-discovery firm Exscientia in 2024, which is where its European operations come from.

Healx is a Cambridge, UK company that applies its Healnet knowledge graph to drug repurposing for rare diseases, the large majority of which have no approved treatment. Its lead programme, a combination therapy for Fragile X syndrome, entered Phase 2 trials after clearance from the FDA.